Recovery / inflammatory research
TB-500 vs KPV
Both are discussed for recovery/inflammation, but neither has identified human drug-product exposure evidence sufficient to establish efficacy or safety.
At a glance
TB-500
KPV
Human evidence
No verified human drug-product exposure or therapeutic outcome dataset for the TB-500 fragment was identified. A 2026 rat Achilles-tendon study provides direct preclinical evidence for the fragment. A ClinicalTrials.gov-style TB-500 record encountered during research explicitly states that it is fictional/example content and is not counted.
FDA reports no identified human drug-product exposure to KPV by any route. Human-derived keratinocyte studies are in vitro and do not constitute clinical exposure.
Research focus
Wound/tissue-repair research claims
Inflammation, gut, skin and wound biology
Regulatory status
Not FDA-approved; FDA has reviewed TB-500-related substances in the compounding context and highlights safety/data gaps.
Not FDA-approved; FDA highlights lack of human exposure and safety data.
Route / formulation
TB-500 fragment evidence must remain separate from full-length thymosin beta-4 and from fictional/example registry content.
Topical, oral and injectable claims should be separated because route changes exposure and risk.
No head-to-head human evidence Both are discussed for recovery/inflammation, but neither has identified human drug-product exposure evidence sufficient to establish efficacy or safety.